Back to Articles

What Is Tesamorelin? Mechanism, Uses, Risks, and FDA Status

May 8, 20265 min readTruPeptide Editorial

What Is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone releasing hormone (GHRH) consisting of all 44 amino acids of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus that improves metabolic stability. Developed by Theratechnologies Inc. and marketed under the brand name Egrifta (and Egrifta SV), it is one of the few peptides with full FDA approval. Tesamorelin was approved in 2010 specifically for the reduction of excess abdominal (visceral) fat in HIV-infected patients with lipodystrophy — a condition characterized by abnormal fat redistribution caused by antiretroviral therapy.

How Does Tesamorelin Work?

Tesamorelin stimulates the natural growth hormone axis through a physiological mechanism:

  • GHRH receptor binding — Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone (Falutz et al., NEJM, 2007)
  • Preserved pulsatility — Unlike exogenous GH injections, tesamorelin maintains the natural pulsatile pattern of GH secretion and preserves negative feedback mechanisms
  • IGF-1 elevation — Increased GH stimulates hepatic IGF-1 production, which mediates many of the metabolic effects
  • Lipolysis activation — GH and IGF-1 promote visceral fat lipolysis (breakdown) preferentially over subcutaneous fat
  • Hepatic fat reduction — Research demonstrates significant reduction in liver fat content, relevant to NAFLD
  • Feedback preservation — The hypothalamic-pituitary axis remains intact, reducing the risk of GH excess compared to direct GH administration

This mechanism makes tesamorelin fundamentally different from synthetic GH (somatropin) — it works with the body's regulatory systems rather than bypassing them.

What Is Tesamorelin Used For?

Based on its FDA-approved indication and published research:

  • HIV-associated lipodystrophy — FDA-approved indication: reduces visceral adipose tissue (VAT) in HIV-infected patients; Phase III trials showed 15–18% reduction in trunk fat (Falutz et al., NEJM, 2007)
  • Non-alcoholic fatty liver disease (NAFLD) — Clinical trial data shows significant reduction in hepatic fat fraction in HIV patients with NAFLD (Stanley et al., Lancet HIV, 2019)
  • Cognitive function — Research in older adults and HIV patients suggests tesamorelin may improve executive function and verbal memory, potentially through IGF-1-mediated neuroprotection (Baker et al., Arch Neurol, 2012)
  • Body composition optimization — Off-label use for visceral fat reduction in non-HIV populations, though this is not an approved indication
  • Peripheral neuropathy — Preliminary research into nerve regeneration through GH/IGF-1 pathway activation
  • Cardiovascular risk markers — Studies show improvements in triglycerides and inflammatory markers alongside visceral fat reduction

What Are the Risks and Side Effects?

  • Injection site reactions — The most common adverse event (reported in up to 8% of patients): erythema, pruritus, pain, and irritation at the injection site
  • Peripheral edema — Fluid retention and swelling, particularly in extremities, related to GH effects
  • Arthralgia — Joint pain reported in approximately 13% of patients in clinical trials
  • Myalgia — Muscle pain reported in some patients
  • Paresthesias — Numbness and tingling, likely related to fluid shifts
  • Carpal tunnel syndrome — GH-related fluid retention can compress the median nerve
  • Glucose metabolism effects — Tesamorelin may impair glucose tolerance; HbA1c monitoring is recommended, particularly in patients with pre-existing diabetes or insulin resistance
  • IGF-1 elevation — Sustained IGF-1 elevation raises theoretical concerns about cellular proliferation; monitoring is recommended
  • Hypersensitivity — Allergic reactions including urticaria and rash have been reported
  • Contraindications — Contraindicated in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis, and hypersensitivity to tesamorelin or mannitol

FDA Status

Tesamorelin is FDA-approved (brand name: Egrifta/Egrifta SV) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It was approved in November 2010 and remains the only GHRH analog with full FDA approval for a metabolic indication. Use for non-HIV indications (general visceral fat reduction, cognitive enhancement, NAFLD) is considered off-label. Tesamorelin is available by prescription and is also accessible through compounding pharmacies. For the latest regulatory updates, visit our FDA tracker.

Key Studies and Evidence Base

| Study | Finding | |-------|---------| | Falutz et al., 2007 (NEJM) | Phase III: 15.2% reduction in visceral fat vs. 5% increase with placebo over 26 weeks in HIV lipodystrophy | | Falutz et al., 2010 (JCEM) | 52-week extension: Sustained visceral fat reduction; fat returned upon discontinuation | | Stanley et al., 2019 (Lancet HIV) | Tesamorelin reduced hepatic fat fraction by 37% in HIV patients with NAFLD over 12 months | | Baker et al., 2012 (Arch Neurol) | Tesamorelin improved executive function and verbal memory in healthy older adults over 20 weeks | | Fourman et al., 2020 (J Infect Dis) | Tesamorelin reduced coronary artery plaque progression in HIV patients |

The Bottom Line

Tesamorelin stands out in the peptide landscape as one of the few compounds with full FDA approval and robust Phase III clinical trial data. Its physiological mechanism — stimulating endogenous GH release rather than replacing it — offers a more nuanced approach to GH-axis modulation. The evidence for visceral fat reduction is strong, and emerging data on liver fat, cognitive function, and cardiovascular markers expands its potential clinical utility. However, it is specifically approved for HIV lipodystrophy, and off-label use should be carefully considered against the risks of glucose impairment and sustained IGF-1 elevation. As an FDA-approved medication, it benefits from established manufacturing standards, dosing guidelines, and post-marketing surveillance that most research peptides lack.

View full compound profile →

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. TruPeptide does not sell peptides or facilitate purchases.